Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD) and Alkermes (ALKS) with bull...

Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Alkermes (ALKS)

Analysts are intrested in these 5 stocks: ( ($SM) ), ( ($CASY) ), ( ($GILD) ), ( ($D) ) and ( ($PODD) ). Here is a breakdown of their recent


SM, Casey’s, Gilead, Dominion, Insulet Trending With Analysts

Jefferies analyst Akash Tewari maintained a Buy rating on Gilead Sciences today and set a price target of $180.00. Tewari covers the Healthcare sec...

Jefferies Remains a Buy on Gilead Sciences (GILD)

Gilead Sciences (($GILD)) has held its Q1 earnings call. Read on for the main highlights of the call. Gilead Sciences’ latest earnings call struck ...

Gilead Sciences Earnings Call Highlights Growth, Deal Drag

Argus Research analyst reiterated a Buy rating on Gilead Sciences on May 15 and set a price target of $165.00. In addition to Argus Research, Gilea...

Argus Research Sticks to Its Buy Rating for Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Henry Schein (HSIC), Insulet (PODD) and Gilead Scien...

Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)

Analysts fell to the sidelines weighing in on Certara (CERT) and Gilead Sciences (GILD) with neutral ratings, indicating that the experts are neith...

Analysts’ Top Healthcare Picks: Certara (CERT), Gilead Sciences (GILD)

In a report released on May 8, Carter Gould from Cantor Fitzgerald maintained a Buy rating on Gilead Sciences, with a price target of $155.00. Acco...

Gilead Sciences (GILD) Receives a Buy from Cantor Fitzgerald

Citi analyst Geoff Meacham maintained a Buy rating on Gilead Sciences on May 7 and set a price target of $165.00. The company’s shares closed last ...

Gilead Sciences (GILD) Receives a Buy from Citi

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Entrada Therapeutics Inc (TR...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Entrada Therapeutics Inc (TRDA) and Contineum Therapeutics, Inc. Class A (CTNM)

Truist Financial analyst Gregory Renza reiterated a Buy rating on Gilead Sciences today and set a price target of $157.00. According to TipRanks, R...

Truist Financial Sticks to Their Buy Rating for Gilead Sciences (GILD)

In a report released today, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences, with a price target of $160.00. Breen covers ...

Bernstein Remains a Buy on Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR), Gilead Sciences (GILD) and ...

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Gilead Sciences (GILD) and Sera Prognostics (SERA)

Gilead Sciences ( ($GILD) ) just unveiled an announcement. At the 2026 annual meeting of stockholders held on April 30, 2026, Gilead Sciences’ inve...

Current Quarter	$-5.31	Next Quarter	$1.75
Current Year	$-0.79	Next Year	$9.58
QoQ Growth	+133.0%	YoY Growth	+1312.7%
3Y EPS CAGR	+23.2%	Target Price	$159.20
Consensus	Buy	Upside	+19.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GILD	$133.73	-0.47%	6.41M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GILD	$133.73	-0.5%	6.41M
3
4
5
6

GILD

GILD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Gilead Sciences Inc. Data in Excel

Get Gilead Sciences Inc. Data in Excel